{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:23:27Z","timestamp":1788985407144,"version":"build-2803163510"},"reference-count":104,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.autrev.2024.103723","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T01:19:09Z","timestamp":1734398349000},"page":"103723","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Deucravacitinib shows superior efficacy and safety in cutaneous lupus erythematosus compared to various biologics and small molecules \u2013 A systematic review and meta-analysis"],"prefix":"10.1016","volume":"24","author":[{"given":"Laura Anna","family":"Bokor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katalin","family":"Martyin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1t\u00e9","family":"Krebs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00e9mi \u00c1gnes","family":"Galajda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanni Ad\u00e9l","family":"Meznerics","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bence","family":"Szab\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Hegyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kende","family":"L\u0151rincz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e1s","family":"B\u00e1nv\u00f6lgyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadett","family":"Hidv\u00e9gi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2024.103723_bb0005","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1111\/j.1365-2133.2011.10272.x","article-title":"Cutaneous lupus erythematosus and the association with systemic lupus erythematosus: a population-based cohort of 1088 patients in Sweden","volume":"164","author":"Gronhagen","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2024.103723_bb0010","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/archdermatol.2009.21","article-title":"Incidence of cutaneous lupus erythematosus, 1965-2005: a population-based study","volume":"145","author":"Durosaro","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.autrev.2024.103723_bb0015","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/acr.23578","article-title":"Racial disparities in the incidence of primary chronic cutaneous lupus erythematosus in the southeastern US: the Georgia lupus registry","volume":"71","author":"Drenkard","year":"2019","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2024.103723_bb0020","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41584-019-0272-0","article-title":"Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies","volume":"15","author":"Wenzel","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2024.103723_bb0025","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1001\/2013.jamadermatol.467","article-title":"Quality of life differences between responders and nonresponders in the treatment of cutaneous lupus erythematosus","volume":"149","author":"Chang","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.autrev.2024.103723_bb0030","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jaad.2010.02.008","article-title":"Quality of life in cutaneous lupus erythematosus","volume":"64","author":"Klein","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2024.103723_bb0035","doi-asserted-by":"crossref","unstructured":"A. Kuhn, Lehmann P., Ruzicka T., Cutaneous lupus erythematosus., 2004.","DOI":"10.1007\/b137847"},{"key":"10.1016\/j.autrev.2024.103723_bb0040","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/j.0022-202X.2005.23889.x","article-title":"The CLASI (cutaneous lupus erythematosus disease area and severity index): an outcome instrument for cutaneous lupus erythematosus","volume":"125","author":"Albrecht","year":"2005","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2024.103723_bb0045","doi-asserted-by":"crossref","first-page":"431","DOI":"10.21037\/atm-20-5048","article-title":"The CLASI, a validated tool for the evaluation of skin disease in lupus erythematosus: a narrative review","volume":"9","author":"Chakka","year":"2021","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.autrev.2024.103723_bb0050","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103723_bb0055","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1177\/0961203314532699","article-title":"Burden of corticosteroid use in patients with systemic lupus erythematosus: results from a Delphi panel","volume":"23","author":"Petri","year":"2014","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2024.103723_bb0060","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/bjd.15312","article-title":"Efficacy and comparison of antimalarials in cutaneous lupus erythematosus subtypes: a systematic review and meta-analysis","volume":"177","author":"Chasset","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2024.103723_bb0065","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/BOR.0000000000001003","article-title":"Emerging biologic therapies for systemic lupus erythematosus","volume":"36","author":"Kato","year":"2024","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2024.103723_bb0070","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti-interferon-alpha receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2024.103723_bb0075","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","article-title":"Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial","volume":"1","author":"Furie","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2024.103723_bb0080","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of Anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2024.103723_bb0085","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa2118024","article-title":"Trial of anti-BDCA2 antibody Litifilimab for cutaneous lupus erythematosus","volume":"387","author":"Werth","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2024.103723_bb0090","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1172\/JCI124466","article-title":"Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus","volume":"129","author":"Furie","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2024.103723_bb0095","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1056\/NEJMoa2118025","article-title":"Trial of anti-BDCA2 antibody Litifilimab for systemic lupus erythematosus","volume":"387","author":"Furie","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2024.103723_bb0100","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2024.103723_bb0105","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2024.103723_bb0110","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/annrheumdis-2017-211631","article-title":"A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea","volume":"77","author":"Zhang","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103723_bb0115","first-page":"1016","article-title":"Efficacy and safety of subcutaneous Belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study, arthritis","volume":"69","author":"Stohl","year":"2017","journal-title":"Rheumatol"},{"key":"10.1016\/j.autrev.2024.103723_bb0120","doi-asserted-by":"crossref","unstructured":"E. Ginzler, L. S. Guedes Barbosa, D. D'Cruz, R. Furie, K. Maksimowicz-McKinnon, J. Oates, et al., Phase III\/IV, Randomized, Fifty-two-week study of the efficacy and safety of Belimumab in patients of black African ancestry with systemic lupus erythematosus Arthritis Rheumatol 74 (2022) 112\u201323, https:\/\/doi.org\/10.1002\/art.41900.","DOI":"10.1002\/art.41900"},{"key":"10.1016\/j.autrev.2024.103723_bb0125","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2024.103723_bb0130","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1093\/rheumatology\/keab381","article-title":"Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus","volume":"60","author":"Furie","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2024.103723_bb0135","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/S0140-6736(18)32167-6","article-title":"Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study","volume":"392","author":"van Vollenhoven","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2024.103723_bb0140","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1136\/ard-2022-222858","article-title":"Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus","volume":"81","author":"van Vollenhoven","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103723_bb0145","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/annrheumdis-2018-eular.6623","article-title":"FRI0328\u00a0targeted therapy using intradermal injection of etanercept for remission induction in discoid lupus erythematosus (TARGET-DLE): first results from a proof-of-concept phase 2 trial","volume":"77","author":"Md Yusof","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103723_bb0150","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1002\/art.38091","article-title":"Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus","volume":"65","author":"Szepietowski","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2024.103723_bb0155","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000581","article-title":"Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study","volume":"9","author":"Furie","year":"2022","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.autrev.2024.103723_bb0160","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1056\/NEJMoa2106535","article-title":"Phase 2 trial of iberdomide in systemic lupus erythematosus","volume":"386","author":"Merrill","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2024.103723_bb0165","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/art.42391","article-title":"Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase ii, randomized, double-blind, placebo-controlled trial","volume":"75","author":"Morand","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2024.103723_bb0170","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Wallace","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2024.103723_bb0175","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(22)02546-6","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)","volume":"401","author":"Petri","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2024.103723_bb0180","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S0140-6736(22)02607-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)","volume":"401","author":"Morand","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2024.103723_bb0185","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1038\/s41467-021-23361-z","article-title":"Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus","volume":"12","author":"Hasni","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.autrev.2024.103723_bb0190","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1093\/rheumatology\/keab685","article-title":"Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study","volume":"61","author":"Werth","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2024.103723_bb0195","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2019"},{"key":"10.1016\/j.autrev.2024.103723_bb0200","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.autrev.2024.103723_bb0205","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"10.1016\/j.autrev.2024.103723_bb0210","author":"R. A., WebPlotDigitizer"},{"key":"10.1016\/j.autrev.2024.103723_bb0215","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.autrev.2024.103723_bb0220","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (minors): development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J Surg"},{"key":"10.1016\/j.autrev.2024.103723_bb0225","first-page":"2127","article-title":"Methodological quality of case series studies: an introduction to the JBI critical appraisal tool","volume":"18","author":"Munn","year":"2020","journal-title":"JBI Evid Synth"},{"key":"10.1016\/j.autrev.2024.103723_bb0230","series-title":"JBI Manual for Evidence Synthesis","article-title":"Chapter 7: Systematic reviews of etiology and risk","author":"Moola","year":"2020"},{"key":"10.1016\/j.autrev.2024.103723_bb0235","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: an approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PLoS Med"},{"key":"10.1016\/j.autrev.2024.103723_bb0240","article-title":"CINeMA: software for semiautomated assessment of the confidence in the results of network meta-analysis","volume":"16","author":"Papakonstantinou","year":"2020","journal-title":"Campbell Syst Rev"},{"key":"10.1016\/j.autrev.2024.103723_bb0245","doi-asserted-by":"crossref","first-page":"544","DOI":"10.7326\/0003-4819-148-7-200804010-00011","article-title":"Exploring the geometry of treatment networks","volume":"148","author":"Salanti","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2024.103723_bb0250","series-title":"A Language and Environment for Statistical Computing","author":"RCT","year":"2023"},{"key":"10.1016\/j.autrev.2024.103723_bb0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v106.i02","article-title":"Netmeta: an R package for network meta-analysis using frequentist methods","volume":"106","author":"Balduzzi","year":"2023","journal-title":"J Stat Softw"},{"key":"10.1016\/j.autrev.2024.103723_bb0260","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s12874-019-0829-2","article-title":"BUGSnet: an R package to facilitate the conduct and reporting of Bayesian network meta-analyses","volume":"19","author":"B\u00e9liveau","year":"2019","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.autrev.2024.103723_bb0265","doi-asserted-by":"crossref","first-page":"425","DOI":"10.36849\/JDD.7098","article-title":"Open-label phase 2 pilot study of oral Tofacitinib in adult subjects with discoid lupus erythematosus (DLE)","volume":"22","author":"Alsukait","year":"2023","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.autrev.2024.103723_bb0270","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jdcr.2021.09.030","article-title":"Oral tofacitinib citrate for recalcitrant cutaneous lupus","volume":"20","author":"Bonnardeaux","year":"2022","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.autrev.2024.103723_bb0275","doi-asserted-by":"crossref","first-page":"421","DOI":"10.25259\/IJDVL_1032_18","article-title":"Successful treatment of two cases of refractory cutaneous lupus erythematosus with belimumab","volume":"87","author":"Bosch-Amate","year":"2021","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.autrev.2024.103723_bb0280","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1177\/09612033231153536","article-title":"Is there an increased risk of severe COVID-19 among patients with systemic lupus erythematosus treated with anifrolumab?","volume":"32","author":"Breillat","year":"2023","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2024.103723_bb0285","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1093\/bjd\/ljad089","article-title":"Rapid efficacy of anifrolumab across multiple subtypes of recalcitrant cutaneous lupus erythematosus parallels changes in discrete subsets of blood transcriptomic and cellular biomarkers","volume":"189","author":"Carter","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2024.103723_bb0290","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jaad.2023.02.044","article-title":"Rapid efficacy of anifrolumab in refractory cutaneous lupus erythematosus","volume":"89","author":"Chasset","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2024.103723_bb0295","doi-asserted-by":"crossref","first-page":"368","DOI":"10.2340\/00015555-1467","article-title":"Ustekinumab in the treatment of refractory chronic cutaneous lupus erythematosus: a case report","volume":"93","author":"Dahl","year":"2013","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.autrev.2024.103723_bb0300","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.revmed.2019.12.004","article-title":"Resistant and progressive cutaneous lupus erythematosus treated with belimumab: a retrospective monocentric study","volume":"41","author":"Dresco","year":"2020","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.autrev.2024.103723_bb0305","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/1346-8138.17027","article-title":"Anifrolumab for systemic lupus erythematosus: a clinical study of Japanese patients in Kanazawa University Hospital","volume":"51","author":"Fushida","year":"2024","journal-title":"J Dermatol"},{"key":"10.1016\/j.autrev.2024.103723_bb0310","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/art.41253","article-title":"Early disease and low baseline damage as predictors of response to Belimumab in patients with systemic lupus erythematosus in a real-life setting","volume":"72","author":"Gatto","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2024.103723_bb0315","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1253279","article-title":"Case report: response of cutaneous lupus lesions in SLE to interferon receptor blockade parallels reduction of interferon score in blood","volume":"14","author":"Gunther","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2024.103723_bb0320","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1177\/09612033231210398","article-title":"Steroid-free flare management of a severe cutaneous lupus flare with anifrolumab","volume":"32","author":"Heide","year":"2023","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2024.103723_bb0325","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.2147\/CCID.S419344","article-title":"Treatment of discoid lupus erythematosus with Upadacitinib: a case report","volume":"16","author":"Hu","year":"2023","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"10.1016\/j.autrev.2024.103723_bb0330","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2017.09.004","article-title":"Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study","volume":"86","author":"Iaccarino","year":"2018","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2024.103723_bb0335","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/acr.22971","article-title":"Effects of Belimumab on flare rate and expected damage progression in patients with active systemic lupus erythematosus","volume":"69","author":"Iaccarino","year":"2017","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2024.103723_bb0340","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/ced.15005","article-title":"Treatment of refractory subacute cuataneous lupus erythematosus with baricitinib","volume":"47","author":"Joos","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.autrev.2024.103723_bb0345","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1080\/14712598.2018.1494719","article-title":"Smoking reduces the efficacy of belimumab in mucocutaneous lupus","volume":"18","author":"Parodis","year":"2018","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.autrev.2024.103723_bb0350","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11123449","article-title":"Rapid response of refractory systemic lupus erythematosus skin manifestations to anifrolumab-a case-based review of clinical trial data suggesting a domain-based therapeutic approach","volume":"11","author":"Pluss","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.autrev.2024.103723_bb0355","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1016\/j.jaad.2020.05.058","article-title":"Belimumab for refractory manifestations of cutaneous lupus: a multicenter, retrospective observational study of 16 patients","volume":"83","author":"Salle","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2024.103723_bb0360","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1001\/jamadermatol.2023.0175","article-title":"Assessment of clinical response to anifrolumab in patients with refractory discoid lupus erythematosus","volume":"159","author":"Shaw","year":"2023","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.autrev.2024.103723_bb0365","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/14397595.2019.1583833","article-title":"Safety and tolerability of anifrolumab, a monoclonal antibody targeting type I interferon receptor, in Japanese patients with systemic lupus erythematosus: a multicenter, phase 2, open-label study","volume":"30","author":"Tanaka","year":"2020","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.autrev.2024.103723_bb0370","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1177\/09612033211033989","article-title":"Belimumab in subacute cutaneous lupus erythematosus","volume":"30","author":"Torrente-Segarra","year":"2021","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2024.103723_bb0375","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1001\/jamadermatol.2022.5242","article-title":"Treatment with anifrolumab for discoid lupus erythematosus","volume":"159","author":"Trentin","year":"2023","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.autrev.2024.103723_bb0380","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1177\/0961203316682097","article-title":"Belimumab for the treatment of recalcitrant cutaneous lupus","volume":"26","author":"Vashisht","year":"2017","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2024.103723_bb0385","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1093\/rheumatology\/keac326","article-title":"Correction to: Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus","volume":"62","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2024.103723_bb0390","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0140-6736(18)31807-5","article-title":"Department of Error","volume":"392","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2024.103723_bb0395","first-page":"e282","article-title":"Correction to Lancet Rheumatol 2022; 4: e282\u201392","volume":"4","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2024.103723_bb0400","doi-asserted-by":"crossref","DOI":"10.3390\/jpm13040691","article-title":"Early and late response and glucocorticoid-sparing effect of Belimumab in patients with systemic lupus erythematosus with joint and skin manifestations: results from the Belimumab in real life setting study-joint and skin (BeRLiSS-JS)","volume":"13","author":"Zen","year":"2023","journal-title":"J Pers Med"},{"key":"10.1016\/j.autrev.2024.103723_bb0405","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3899\/jrheum.210805","article-title":"Efficacy and safety of Ustekinumab in patients with active systemic lupus erythematosus: results of a phase II open-label extension study","volume":"49","author":"van Vollenhoven","year":"2022","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2024.103723_bb0410","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/art.41179","article-title":"Maintenance of efficacy and safety of Ustekinumab through one year in a phase II multicenter, prospective, randomized, double-blind, placebo-controlled crossover trial of patients with active systemic lupus erythematosus","volume":"72","author":"van Vollenhoven","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2024.103723_bb0415","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/mr\/roac010","article-title":"The efficacy and safety of anifrolumab in Japanese patients with systemic lupus erythematosus: TULIP-2 subanalysis","volume":"33","author":"Tanaka","year":"2023","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.autrev.2024.103723_bb0420","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1016\/S2665-9913(21)00317-9","article-title":"Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials","volume":"4","author":"Morand","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2024.103723_bb0425","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2018-000284","article-title":"Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus","volume":"5","author":"Merrill","year":"2018","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.autrev.2024.103723_bb0430","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1177\/09612033211014267","article-title":"Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus","volume":"30","author":"Furie","year":"2021","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2024.103723_bb0435","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2022-000761","article-title":"Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials","volume":"10","author":"Bruce","year":"2023","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.autrev.2024.103723_bb0440","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1111\/bjd.20597","article-title":"British Association of Dermatologists guidelines for the management of people with cutaneous lupus erythematosus 2021","volume":"185","author":"O\u2019Kane","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2024.103723_bb0445","first-page":"1371","article-title":"S2k guideline: diagnosis and management of cutaneous lupus erythematosus - part 2: therapy, risk factors and other special topics","volume":"19","author":"Worm","year":"2021","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.autrev.2024.103723_bb0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2021.102707","article-title":"Guideline for the diagnosis, treatment and long-term management of cutaneous lupus erythematosus","volume":"123","author":"Lu","year":"2021","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2024.103723_bb0455","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11926-020-00946-z","article-title":"An update on the pathogenesis of cutaneous lupus erythematosus and its role in clinical practice","volume":"22","author":"Patel","year":"2020","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.autrev.2024.103723_bb0460","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2018-000261","article-title":"Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus","volume":"5","author":"Riggs","year":"2018","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.autrev.2024.103723_bb0465","article-title":"Current concepts on pathogenic mechanisms and histopathology in cutaneous lupus erythematosus","volume":"9","author":"Fetter","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.autrev.2024.103723_bb0470","doi-asserted-by":"crossref","first-page":"903","DOI":"10.4049\/jimmunol.1700418","article-title":"IL-23 limits the production of IL-2 and promotes autoimmunity in lupus","volume":"199","author":"Dai","year":"2017","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2024.103723_bb0475","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1305590","article-title":"Th1-related transcription factors and cytokines in systemic lupus erythematosus","volume":"14","author":"Tang","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2024.103723_bb0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104840","article-title":"Allosteric TYK2 inhibition: redefining autoimmune disease therapy beyond JAK1-3 inhibitors","volume":"97","author":"Jensen","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.autrev.2024.103723_bb0485","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003991","article-title":"Modifying T cell phenotypes using TYK2 inhibitor and its implications for the treatment of systemic lupus erythematosus","volume":"10","author":"Satoh-Kanda","year":"2024","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2024.103723_bb0490","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1002341","article-title":"Association of NCF2, IKZF1, IRF8, IFIH1, and TYK2 with systemic lupus erythematosus","volume":"7","author":"Cunninghame Graham","year":"2011","journal-title":"PLoS Genet"},{"key":"10.1016\/j.autrev.2024.103723_bb0495","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1600-0625.2009.00982.x","article-title":"Tyrosine kinase 2 and interferon regulatory factor 5 polymorphisms are associated with discoid and subacute cutaneous lupus erythematosus","volume":"19","author":"Jarvinen","year":"2010","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.autrev.2024.103723_bb0500","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/s41584-024-01093-w","article-title":"TYK2: an emerging therapeutic target in rheumatic disease","volume":"20","author":"Morand","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2024.103723_bb0505","doi-asserted-by":"crossref","first-page":"464","DOI":"10.15252\/emmm.201404719","article-title":"Anti-BDCA2 monoclonal antibody inhibits plasmacytoid dendritic cell activation through fc-dependent and fc-independent mechanisms","volume":"7","author":"Pellerin","year":"2015","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.autrev.2024.103723_bb0510","doi-asserted-by":"crossref","first-page":"14158","DOI":"10.3390\/ijms160614158","article-title":"A Plasmacytoid dendritic cells-type I interferon axis is critically implicated in the pathogenesis of systemic lupus erythematosus","volume":"16","author":"Kim","year":"2015","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2024.103723_bb0515","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/s41591-021-01458-8","article-title":"Accelerating the translational medicine cycle: the academia Europaea pilot","volume":"27","author":"Hegyi","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2024.103723_bb0520","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9051532","article-title":"Academia Europaea position paper on translational medicine: the cycle model for translating scientific results into community benefits","volume":"9","author":"Hegyi","year":"2020","journal-title":"J Clin Med"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997224002143?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997224002143?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,16]],"date-time":"2025-02-16T15:11:45Z","timestamp":1739718705000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997224002143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":104,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1568997224002143"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2024.103723","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Deucravacitinib shows superior efficacy and safety in cutaneous lupus erythematosus compared to various biologics and small molecules \u2013 A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2024.103723","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103723"}}